Blockade of IL-3 is a promising novel strategy for RA therapy
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory
disorder that attacks the joints producing an inflammatory synovitis. About 1% of the world‘s population is afflicted by rheumatoid arthritis, which is associated with high costs and, if not treated appropriately, with a reduction in life expectancy. Current treatment options include small molecules like methotrexate or biologics like TNFa-blockers, but about 20 % of patients show little or no response to currently available therapies or suffer from severe long term side effects like infections (i.e. tuberculosis, viral brain infections) or cancer (i.e. lymphomas). Clearly, an effective RA drug has blockbuster potential as shown by TNFa-blocker Humira® (Abbott Laboratories) with annual worldwide sales of 4.5 Billion USD in 2008 (data by Medtrack).
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work
Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…
New SPECT/CT technique shows impressive biomarker identification
…offers increased access for prostate cancer patients. A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more…
How 3D printers can give robots a soft touch
Soft skin coverings and touch sensors have emerged as a promising feature for robots that are both safer and more intuitive for human interaction, but they are expensive and difficult…
